Severe Arthropathy With a Grossly Deficient Rotator Cuff Clinical Trial
Official title:
A Prospective Multicenter Study to Examine the Influence of Repairing the Sub-scapularis on Outcomes After Reverse Arthroplasty: A Randomized, Controlled Trial.
Verified date | March 2022 |
Source | Encore Medical, L.P. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a prospective, multi-center, randomized blinded study to determine how repairing the subscapularis vs. not repairing the subscapularis when subjects are implanted with the AltiVate Reverse® Shoulder System for reverse total shoulder arthroplasty affects isometric and isokinetic internal rotational strength. It is hypothesized that patients in which the subscapularis is repaired will have improved postoperative isometric and isokinetic internal rotational strength.
Status | Enrolling by invitation |
Enrollment | 200 |
Est. completion date | December 31, 2028 |
Est. primary completion date | December 31, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is =21 years of age 2. Subject is scheduled for reverse shoulder arthroplasty with the AltiVate Reverse device due to primary diagnosis of severe arthropathy with a grossly deficient rotator cuff 3. Subject's sub scapularis has been determined from MRI to be sufficient to repair 4. Subject is willing and able to comply with the study schedule and assessments 5. Subject is likely to be available for evaluation for the duration of the study 6. Subject is willing and able to sign the informed consent Exclusion Criteria: 1. Subject is indicated for reverse shoulder arthroplasty for other indications (revision arthroplasty, proximal humerus fracture, etc.), addition of latissimus transfer or pectoralis major transfer 2. Subject has metal allergies or sensitivity 3. Subject has an active infection at or near the site of implantation 4. Subject has a nonfunctional deltoid muscle 5. Subject has neuromuscular compromise condition of the shoulder 6. Subject has known active metastatic or neoplastic diseases, Paget's disease or Charcot's disease 7. Subject is currently on or planning to be on chemotherapy or radiation 8. Subject has had chemotherapy or radiation within the last 6 months 9. Subject is currently taking > 5mg/day corticosteroids (e.g. prednisone), excluding inhalers, within 3 months prior to surgery 10. Female subjects who are pregnant or planning to become pregnant within the study period 11. In the investigator's opinion, the subject is unable to understand the study or be compliant with the follow up or has a history of non-compliance with medical advice 12. Subject has a history of any cognitive or mental health status that would interfere with study participation 13. Subject is abusing alcohol or drugs or is undergoing active treatment for substance abuse (e.g., recreational drugs, narcotics, or alcohol). |
Country | Name | City | State |
---|---|---|---|
United States | Texas Orthopedic Group | Houston | Texas |
United States | NYU Langone Center for Musculoskeletal Care | New York | New York |
United States | Rothman Institute | Philadelphia | Pennsylvania |
United States | St. Luke's Hospital | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Encore Medical, L.P. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in isometric and isokinetic internal rotational strength of abductors | Maximal isometric strength of shoulder abductors and measured in kilograms using a force gauge | 6 months, and 1, 2, 5 and 10 years | |
Primary | Change in isometric and isokinetic internal rotational strength of flexors | Maximal isometric strength of shoulder flexors measured in kilograms using a force gauge | 6 months, and 1, 2, 5 and 10 years | |
Primary | Change in isometric and isokinetic internal rotational strength of internal rotators | Maximal isometric strength of shoulder measured internal rotators in kilograms using a force gauge | 6 months, and 1, 2, 5 and 10 years | |
Primary | Change in isometric and isokinetic internal rotational strength of external rotators | Maximal isometric strength of shoulder measured external rotators in kilograms using a force gauge | 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder ROM with the AltiVate Reverse® Shoulder | Examine operative shoulder active forward elevation | 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder ROM with the AltiVate Reverse® Shoulder | Examine operative shoulder active abduction | 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder ROM with the AltiVate Reverse® Shoulder | Examine operative shoulder active external rotation | 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder ROM with the AltiVate Reverse® Shoulder | Examine operative shoulder active internal rotation | 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder functionality with the AltiVate Reverse® Shoulder | Examine change in ASES score | 6 weeks,6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder functionality with the AltiVate Reverse® Shoulder | Examine change in pain per ASES assessment | 6 weeks, 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in shoulder functionality with the AltiVate Reverse® Shoulder | Examine change in SST score | 6 weeks,6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in general health with the AltiVate Reverse® Shoulder | Examine change in VR-12 | 6 weeks, 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate change in the radiographs of AltiVate Reverse® Shoulder | Examine radiographic parameters | 6 weeks, 6 months, and 1, 2, 5 and 10 years | |
Secondary | To evaluate device survivorship of the AltiVate Reverse® Shoulder | Examine adverse events | 6 weeks, 6 months, and 1, 2, 5 and 10 years |